(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Moving Pool Highlights for 2024 - 2Favored Chinese Dish: Make Your Determination
- 3Russian billionaire says 12-hour days and 6-day workweeks could help save the economy
- 4The most effective method to Keep up with Proficient Handshakes in a Computerized World
- 5Which Kind of Pet Makes the Incomparable Buddy?
- Feeling wonder every day improves our health. Here’s how to do it.
- Historic underwater structure discovered by divers off French coast
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- Instructions to Expand Your Advantages from an Open Record Reward
- Figure out How to Back Your Rooftop Substitution
- Bondi Beach survivor criticizes police for inaction during terror attack
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- Make your choice for a definitive Christmas getaway destination!
- Help Your Efficiency with These Work area Updates
